GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

Rhea-AI Summary

GRAIL (Nasdaq: GRAL) will report fourth quarter and full year 2025 financial results after market close on Thursday, Feb. 19, 2026.

Management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress. According to the company, a live webcast and recorded replay will be available at the investor relations site and open to all.

Key Figures

Total revenue: $36.2M U.S. Galleri revenue: $32.6M Galleri tests sold: >45,000 +5 more

8 metrics

Total revenue $36.2M Q3 2025 total revenue, +26% YoY

U.S. Galleri revenue $32.6M Q3 2025, +28% YoY

Galleri tests sold >45,000 Q3 2025 tests sold, +39% YoY

Net loss $89.0M Q3 2025 net loss

Adjusted EBITDA $(71.7)M Q3 2025 adjusted EBITDA

Adjusted gross profit $20.0M Q3 2025 adjusted gross profit

Private placement $325M Capital raised via private placement, reported with Q3 2025

Cash position >$850M Cash runway into 2030, as of Q3 2025

Market Reality Check

Price: $97.50 Vol: Volume 441,793 is 0.55x t...

low vol

$97.50 Last Close

Volume Volume 441,793 is 0.55x the 20-day average of 803,830 shares. low

Technical Price at $97.50 is trading above the 200-day MA of $63.49, and about 17.96% below the 52-week high.

Peers on Argus

GRAL is up 1.68% with light volume. Peers in Diagnostics & Research are also pos...

GRAL is up 1.68% with light volume. Peers in Diagnostics & Research are also positive (e.g., TWST +3.13%, CDNA +1.29%, OPK +0.82%, NEO +0.53%, NEOG +0.64%), but none appeared in the momentum scanner.

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	PMA submission	Positive	-3.1%	Filed final PMA module for Galleri multi-cancer early detection test.
Dec 15	Conference presentation	Neutral	-4.4%	Announced management presentation at J.P. Morgan Healthcare Conference.
Dec 01	Inducement grants	Neutral	-0.9%	Granted 21,570 RSUs to 21 non-executive employees under inducement plan.
Nov 18	Conference presentation	Neutral	-4.1%	Planned presentation at Piper Sandler 37th Annual Healthcare Conference.
Nov 12	Quarterly earnings	Positive	+1.6%	Reported Q3 2025 revenue growth, Galleri expansion, financing, and strong cash.

Pattern Detected

Recent news often saw negative or muted price reactions, even around conferences and regulatory milestones, with only the last earnings report showing a positive move.

Recent Company History

Over the last few months, GRAIL reported multiple corporate and regulatory milestones. On Nov. 12, 2025, Q3 2025 results showed revenue of $36.2M, U.S. Galleri revenue of $32.6M, and a net loss of $89.0M, alongside a ~$325M private placement, a planned $110M Samsung investment, and cash above $850M. Subsequent updates included conference presentations, inducement grants, and a key PMA submission for Galleri on Jan. 29, 2026, which drew a negative price reaction despite its importance.

Market Pulse Summary

This announcement sets the timetable for GRAIL’s detailed Q4 and full-year 2025 financial disclosure...

Analysis

This announcement sets the timetable for GRAIL’s detailed Q4 and full-year 2025 financial disclosure, following earlier preliminary information shared at the 2026 J.P. Morgan Healthcare Conference and the Q3 2025 report highlighting $36.2M in revenue and cash above $850M. Investors may focus on revenue growth trends, Galleri test adoption, net loss progression, and updates following the recent PMA submission to gauge how the business and regulatory story are evolving.

AI-generated analysis. Not financial advice.

MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year 2025 following the close of market on Thursday, Feb. 19, 2026. Following the release, company management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress.

Fourth Quarter and Full Year 2025 Webcast and Conference Call Details

A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.  

Please register for the live event at https://grail-q4-financial-results-2025.open-exchange.net/

To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results-302688442.html

SOURCE GRAIL, Inc.

FAQ

When will GRAIL (GRAL) release its Q4 and full year 2025 results?

GRAIL will release fourth quarter and full year 2025 results after market close on Feb. 19, 2026. According to the company, the release timing is intended to allow an immediate management webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.

What time is the GRAIL (GRAL) earnings webcast and conference call on Feb. 19, 2026?

The webcast and conference call are scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Feb. 19, 2026. According to the company, management will discuss financial results and business progress during that live event and take questions.

How can investors access the GRAIL (GRAL) live webcast and replay for Q4 2025?

Investors can access the live webcast and recorded replay via the investor relations section at investors.grail.com. According to the company, a link will be provided on the site and the replay will remain available after the live event.

Is registration required to join GRAIL's (GRAL) Q4 2025 teleconference and webcast?

The company asks participants to register for the teleconference and webcast prior to the event and join at least ten minutes early. According to the company, registration helps ensure timely connection and smooth access for attendees.

Will the GRAIL (GRAL) Q4 2025 webcast be open to the public?

Yes, the live webcast and recorded replay are open to all interested parties. According to the company, no investor qualification is required and the materials will be posted on the investor relations website for public access.

Where should I register to attend GRAIL's (GRAL) Feb. 19, 2026 earnings call?

Register for the live event at the provided registration link before the call and join the webcast on time. According to the company, the registration URL is listed in the announcement and on the investor relations site for convenience.